
Insurers denied 39% of pediatric allergy, asthma biologic requests
Key Takeaways
- More than 9 in 10 pediatric biologic prescriptions for atopic disease required prior authorization, and 39.3% of those requests were denied in this single-center review.
- Approval took a mean of nearly 33 days, a meaningful delay for children whose disease is already uncontrolled on standard therapy.
At ACAAI 2026, 93.6% of pediatric biologic prescriptions needed prior authorization, 39.3% were denied, and approval took a mean of 33 days.
For children with uncontrolled asthma, atopic dermatitis, chronic urticaria, or IgE-mediated food allergy, getting an insurer to cover a prescribed biologic took more than a month on average, and nearly 4 in 10 prior authorization (PA) requests were denied, according to a retrospective analysis presented at the American College of Allergy, Asthma and Immunology (ACAAI) 2026 Annual Scientific Meeting in Phoenix, Arizona.¹
"When a child's asthma or allergies are out of control, every week counts," said allergist Aarti Pandya, MD, a study co-author and ACAAI member.¹ She noted that by the time a biologic is prescribed, the physician and family have already agreed it is the right treatment, and that delays of this length can expose children to serious health problems.¹
Prior authorization and denial rates for pediatric biologics
Investigators reviewed the charts of 326 biologic prescriptions written by allergists at a tertiary care pediatric center in Kansas City, Missouri, between 2018 and 2026.¹ Agents included omalizumab, mepolizumab, benralizumab, dupilumab, and tezepelumab; omalizumab accounted for 182 prescriptions (55.8%) and dupilumab for 85 (26.0%).¹ Patients had a median age of 11.4 years, and the cohort was evenly split by sex (50.3% male).¹
Overall, 93.6% of prescriptions required PA, and 39.3% of those requests were denied.¹ The most common denial reasons were failure to meet insurer criteria (24.4%) and a requirement to first try a prerequisite medication (23.4%).¹ The mean interval from prescription to approval was 32.65 days.¹
The authors concluded that the gap between prescribing and approval may put patients at risk of serious health outcomes and called for policy changes to the PA process.¹ Pandya said the team hopes the data prompt discussion about making approvals faster and simpler.¹
Biologic therapy for pediatric asthma and atopic disease
About 6.7% of US children younger than 18 years had current asthma in 2023.⁴ Biologics—monoclonal antibodies directed at IgE (omalizumab), interleukin (IL)-5 or its receptor (mepolizumab, benralizumab), the IL-4 receptor α subunit (dupilumab), or thymic stromal lymphopoietin (tezepelumab)—are generally reserved for moderate to severe disease that remains poorly controlled on standard therapy.¹ ² As a result, children waiting on approval are, by definition, those whose disease has not responded adequately to conventional treatment.
Pediatric findings mirror earlier biologic access data in asthma
The results are consistent with prior work. A 2-center study of biologics prescribed for moderate to severe asthma between 2018 and 2020 found initial denial rates of 38.8% at Montefiore Medical Center and 24.7% at Scripps Clinic, with a median of 34 days from prescription to administration at both sites.² In that analysis, appeals substantially lengthened time to approval.²
Concerns about PA extend beyond allergy. In the American Medical Association's 2024 survey of 1,000 practicing physicians, 94% said PA delays access to care, and 24% reported that it had led to a serious adverse event for a patient.³
For clinicians, the findings suggest that PA should be anticipated for virtually every pediatric biologic prescription. Documenting prior therapies, disease severity, and payer-specific criteria at the time of prescribing may help reduce denials tied to unmet criteria or step-therapy requirements, although the abstract did not test such strategies directly.
References
American College of Allergy, Asthma and Immunology. Insurance delays and denials mean kids don't get allergy and asthma medications. News release. November 12, 2026. Accessed November 17, 2026.
https://acaai.org/news/insurance-delays-and-denials-mean-kids-dont-get-allergy-and-asthma-medications/ Sehanobish E, Ye K, Imam K, et al. Elaborate biologic approval process delays care of patients with moderate-to-severe asthma. J Allergy Clin Immunol Glob. 2023;2(2):100076.
doi:10.1016/j.jacig.2022.10.007 Henry TA. Prior authorization delays care—and increases health care costs. AMA News Wire. August 9, 2024. Accessed November 17, 2026.
https://www.ama-assn.org/practice-management/prior-authorization/prior-authorization-delays-care-and-increases-health-care National Center for Health Statistics. FastStats: asthma. Centers for Disease Control and Prevention. Accessed November 17, 2026.
https://www.cdc.gov/nchs/fastats/asthma.htm
Related to this article








